Androgen receptor antagonists and anti-prostate cancer activities of some newly synthesized substituted fused pyrazolo-, triazolo- and thiazolo-pyrimidine derivatives

• Published in: International journal of molecular sciences Vol. 15; no. 11; pp. 21587 - 21602
• Main Authors: Bahashwan, Saleh A, Fayed, Ahmed A, Ramadan, Mohamed A, Amr, Abd El-Galil E, Al-Harbi, Naif O
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.11.2014; MDPI
• Subjects: Androgen Receptor Antagonists - pharmacology; Androgens; Animals; anticancer activities; Antineoplastic Agents - pharmacology; Cell Line; Cell Line, Tumor; Chemical compounds; Chemical synthesis; CHO Cells; Cricetulus; Humans; Lethal Dose 50; Male; naphthalinothiazolohydrazine; Pharmaceutical sciences; Prostate cancer; Prostatic Neoplasms - drug therapy; Pyrazoles - pharmacology; pyrazolopyrimidine; Pyrimidines - pharmacology; Thiazoles - pharmacology; thiazolopyrimidine; Triazoles - pharmacology
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms151121587

A series of substituted pyrazole, triazole and thiazole derivatives (2-13) were synthesized from 1-(naphtho[1,2-d]thiazol-2-yl)hydrazine as starting material and evaluated as androgen receptor antagonists and anti-prostate cancer agents. The newly synthesized compounds showed potent androgen receptor antagonists and anti-prostate cancer activities with low toxicity (lethal dose 50 (LD50)) comparable to Bicalutamide as reference drug. The structures of newly synthesized compounds were confirmed by IR, 1H-NMR, 13C-NMR, and MS spectral data and elemental analysis. The detailed synthesis, spectroscopic data, LD50 values and pharmacological activities of the synthesized compounds are reported.